AAIC 2024 - What Will Happen at the World’s Largest Conference for Alzheimer's Disease?

With an increasing focus on Alzheimer’s disease research and treatment, the Alzheimer’s Association International Conference (AAIC), the world’s largest meeting dedicated to advancing dementia science, returns to Philadelphia this summer from July 28th-August 1st.

 

The annual event brings together researchers, clinicians, and dementia professionals to share ideas and showcase breakthrough research discoveries and improvements in the prevention, treatment, and diagnosis of Alzheimer’s disease.

 

See VUNO’s press release announcing 3 upcoming poster presentations at AAIC 2024.

 

Recap of the 2023 AAIC Conference

 

Last year’s conference took place in the Netherlands, bringing 10,000 attendees and more than 3,000 scientific presentations in-person and virtually. With registration still open for 2024, AAIC is now in the U.S.!

 

American professionals will have more opportunities to learn from their overseas counterparts in 2024: at the 2024 conference, 6 main speakers will be from outside the U.S., compared to 2 in 2023. 

 

To help attendees prepare for AAIC 2024, the VUNO team gathered an overview of all upcoming sessions for consideration. 

 

In-Person Workshops and Pre-Conferences at AAIC 2024

 

Before the start of the main conference, AAIC 2024 will offer in-person workshops and pre-conferences from July 25th to 27th. These will give attendees the opportunity to explore and educate themselves on breakthrough findings and new practices that advance the prevention and treatment of Alzheimer’s disease and other dementias. 

 

The workshop, “Improving Public Health Action on Brain Health: A Public Health Center of Excellence Workshop on How to Effect Change,” will focus on modifiable risk factors that can improve brain health and review how public health can better educate people about and promote brain health. 

 

The workshop is sponsored by the Public Health Center of Excellence on Dementia Risk Reduction at the Alzheimer’s Association, which is funded by the U.S. Centers for Disease Control and Prevention (CDC), and is a great learning opportunity for all attendees. 

 

Click here to review the full program for workshops.

 

2024 Scientific Sessions 

 

One of the main events at AAIC is the Scientific Sessions, which include Plenary Speaker and Perspectives sessions. These sessions feature podiums and poster presentations that focus on science and pathogenesis, biomarkers, clinical manifestations, drug development, public health, dementia care, and the latest Alzheimer’s research. 

 

Dr. Cynthia Lemere’s Plenary Session “The Evolving Role of Complement in Alzheimer’s Disease” at AAIC 2023

Plenary Speaker Sessions

 

The Scientific Sessions also include the Plenary Speaker Sessions, featuring discussions on advancements in Alzheimer’s research and care. This year’s speakers include Edward B. Lee, Timothy Miller, and Reisa Sperling. 

 

Dr. Lee will present the topic “Neuropathology in a Multidisciplinary Age” on the first day of the conference. Dr. Lee is a Professor of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania and is the Co-Director of the university’s Institute on Aging, specializing in Neuropathology, Cancer and Immunobiology.

 

Another 2024 Plenary Speaker, Timothy Miller, will present “Antisense Oligonucleotide Therapeutics for Neurodegenerative Diseases.” Dr. Miller is an experienced Neurologist at Washington University School of Medicine in St. Louis, where he leads the Miller Laboratory and the ALS Center. 

 

Reisa Sperling, a Neurologist at Harvard Medical School and Co-Principal Investigator of the Harvard Aging Brain Study in Boston. Her research focuses on the detection and treatment of Alzheimer’s disease and has led multiple Alzheimer’s clinical trials. She will present the session, “Preclinical Alzheimer’s Dementia.” 

 

Perspectives Sessions

 

Perspectives Sessions provide expert reviews of recent dementia-related advances and plans for the future of Alzheimer’s care and treatment. Perspectives Sessions at AAIC 2024 will include: 

 

  • Translating AD biomarkers into clinical practice in an era of precision medicine

 

  • Future perspectives on how to conduct clinical trials in Alzheimer’s disease: Where do we go from here?

 

  • Dementia and the provision of care: diverse lived experiences across the Black/African diaspora

 

Industry leaders will discuss, review, and debate these topics to advance Alzheimer’s care and treatment.

 

View full information on the Scientific Sessions here. 

 

Emerging Concepts in Basic Science

 

The Emerging Concepts in Basic Science focuses specifically on dementia science. This series will explore three concepts:

 

1. The Causes and Consequences of Tau Aggregation in Tauopathies 

Chaired by Bradley Hyman and Maria Grazia Spillantini, includes 4 sessions, such as Tau Post-Translational Modifications, presented by Judith Steen.

 

2. Immune Cells Diversity and Their Role in Cognition and Dementia 

Chaired by David Holtzman and Diego Gomez-Nicola, features 4 sessions, including Diversity and Function of Brain Macrophages in Alzheimer’s Disease, presented by Kiavash Movahedi.

 

3. Spatial Biology in Neurodegenerative Proteinopathies: Uncovering Resilience vs. Vulnerability 

Chaired by Bart DeStrooper and Lea T. Grinberg, 4 sessions will cover topics like Charting New Paths: The Role of Spatial Omics in Advancing Neurodegenerative Disease Research, presented by Rebecca Hodge.

 

Check out the full list of Emerging Concepts in Basic Science sessions here.

 

Visit booth #1411 to experience VUNO Med®-DeepBrain®

VUNO CEO Ye-ha Lee 

 

This year, AAIC will host 117+ exhibitors leading the global medical and scientific dementia industry. 

 

Find the full list of AAIC exhibitors here 

 

Widely acclaimed as a true pioneer in AI-based medical solutions, VUNO will exhibit the FDA-cleared imaging solution VUNO Med®-DeepBrain® at booth #1411. 

 

VUNO Med®-DeepBrain® a highly accurate and fast atrophy and WMH measurement AI solution to assist diagnosis of neurodegenerative diseases. the fastest, most accurate AI-based software for quantitative analysis of the brain on the market. 

 

At AAIC 2023, VUNO had the honor of presenting a poster titled “Brain Volumetry-based Amyloid PET Positivity Prediction in Subjective Cognitive Decline Patients” during the pre-conference and conference sessions. 

 

Interested in trying a demo of VUNO Med®-DeepBrain® before AAIC 2024? Book a Free Demo with our team. Connect with us for joint research projects or for any questions on AI assistants for imaging professionals.

 

 

Sources:

VUNO wins top spot in global AI glaucoma screening challenge at ISBI 2024

Enhancing the accuracy of diagnosis while reducing subjectivity through VUNO Med®-DeepBrain®

Over the past 5 years, Dr. Chong Hyun Suh, a neuroradiologist at ASAN Medical Center, has utilised VUNO Med®-DeepBrain® to diagnose and monitor dementia patients. He says VUNO…[READ MORE]

In My Experience, VUNO Med®-DeepBrain® is an Invaluable Tool for Brain Volumetry

“I have been routinely utilizing VUNO Med®-DeepBrain® in my clinical practice for the past 3 years. The Brain Volumetry Results Report, generated from 3D T1 MPRAGE images, can…[READ MORE]

Request a Demo

Leave an inquiry

"*" indicates required fields

How did you hear about VUNO?**

Private & Cookie Policy

 

VUNO Inc. (hereinafter referred to as the “Company”) has this Privacy Policy (hereinafter referred to as the “Policy”) in place to protect user privacy, rights and interests; and handle user complaints relevant to personal information in accordance with the Personal Information Protection Act.

※ This Policy, as partially modified and updated, goes into effect on November 9 2020.

Article 1 Purpose of Processing Personal Information

The Company processes personal information for the following purposes.

  1. To provide the Company’s services: Provision of the Company’s services owing to offline product purchase and purchase inquiry; prevention of service misappropriation; sending of notifications including e-mailing; product delivery; dispatch of contracts and invoices; payment and settlement of fees; provision of customized services including newsletters; etc.
  2. To deal with collaborative tasks and external activities concerning research and public relations: Sharing information on products and product demonstration events organized by the Company; preliminary review of identification and other matters to entrust services such as research, speeches and consultation; signing and fulfillment of the pertinent contracts; tax withholding; product-related marketing and research activities; etc.
  3. To recruit employees: Execution of applicant screenings and sending of notifications for each step of the pertinent process; review of job candidates for year-round hiring who agree to register for VUNO Talent Pool; handling of complaints and sending of notifications on the results thereof in the event of inquiries being made on recruitment; etc.
  4. To handle complaints and product information including safety thereof: Answering product inquiries; identification check of a person who lodges a complaint; review of complaint details; contacting the said person for fact-finding inspection and notifications on the pertinent results; reporting, assessment and handling of matters on product safety and quality complaints; etc.
  5. To fulfill legal and administrative obligations: Fulfillment of obligations to report and submit documentation of clinical testing and post-market safety management including post market surveillance pursuant to relevant statutes including the Medical Service Act, the Medical Devices Act and the Bioethics and Safety Act; declaration and payment of taxes such as corporate tax and value added tax; issuance and transfer of bills, receipts and tax invoices; delivering on legal and administrative obligations according to relevant statutes, and orders and commands issued by administrative authorities and other related agencies; etc.
  6. To manage visual data processing: Provision of on-premises security; prevention of fire and crime; etc.

 

The Company processes de-identified data for the purpose of research and development of AI software programs. Health and medical records that are used for research purposes do not include any personally identifiable information such as a full name and phone number. The Company uses such data for scientific research only.

The Company may use and provide personal information of a data subject within the scope reasonably related to the purposes for which the said personal information was initially collected, in accordance with the Personal Information Protection Act taking into consideration whether disadvantages are caused to the data subject; whether necessary measures to secure safety such as encryption have been taken; etc. Use and provision of personal information is firmly based on the Company’s comprehensive consideration into miscellaneous circumstances: The Personal Information Protection Act and other relevant statutes; The purposes and methods of using and providing personal information; Particulars of personal information to be used and provided;

Particulars of personal information in the event that consent for use and provision thereof is obtained from a data subject; or that any notification or disclosure has been made to a data subject thereon; The impact on the privacy of a data subject due to use and provision of personal information thereof; Measures that are in place to protect personal information to be used and provided.

  • Whether there is any relevance to the purposes for which the personal information was initially collected;
  • Whether there is any predictability of additional use or provision of personal information considering circumstances under which the said personal information is collected or the processing practices thereof;
  • Whether the interests of a data subject are unfairly infringed on;
  • Whether necessary measures to secure safety such as pseudonymization or encryption have been taken.

 

Article 2 Period for Processing and Retaining Personal Information

  1. The Company may retain and use personal information until the purposes of processing the said personal information are fulfilled within the period for retaining and using personal information: prescribed by statutes; or for which consent is obtained from a data subject at the time of personal information collection. Such data shall be destroyed without delay when the aforementioned purposes of processing are attained.
  1. General information concerning medical professionals including doctors: Until a service agreement regarding product purchase expires;
  2. Data concerning user complaints and reports on adverse events and other safety and quality issues: Three years from the date of reporting;
  3. General data on job candidates: Three years from the date of the submission of a job application document;
  4. General data regarding subcontractors and suppliers: Until the execution of services regarding a contract, project or proposal finishes;
  5. Sending of newsletters: Three year from the date of the subscription to newsletters.

 

  1. In the event that personal information protection is deemed necessary pursuant to relevant statutes including the Commercial Act and the Protection of Communications Secrets Act, the Company may share personal information within the period for retaining and using personal information prescribed by the aforesaid statutes.
  • All important documents relating to the Company’s business

Legal grounds for retention: The Commercial Act

Retention period: Ten years

  • Website browsing history

Legal grounds for retention: The Protection of Communications Secrets Act

Retention period: Three months

Article 3 Provision of Personal Information to Third Parties

  1. The Company may in principle process personal information within the scope prescribed by Article 1 of the Policy. Without the consent of a data subject, the Company shall not process the personal information of the said data subject beyond the aforementioned scope, nor provide such data to any third party, except in any of the following circumstances.
  1. Where prior consent of a data subject is obtained for provision and disclosure of information to third parties;
  2. Where provision of personal information is deemed mandatory or allowable pursuant to statutes.

 

  1.  [Researchers who belong to clinical testing organizations]

Recipient

Purpose of provision

Particulars to be provided

Period for retention and use

Ministry of Food and Drug Safety

To submit clinical testing plans on medical devices; and fulfill the duty to report according to relevant statutes including the Medical Devices Act

Names, organizations, majors, positions and contact points of persons in charge of testing, experimenters and co-researchers   

Until the purposes herein stated are attained

 

Article 4 Outsourcing of Personal Information Processing

  1. The Company outsources personal information processing to a third party as below to facilitate the execution of processing.

Outsourcee

Particulars of outsourced work

MIDAS Information Technology Co., Ltd.

To manage a recruitment webpage and employment procedures

To run a computing system and handle relevant complaints

  1. In accordance with Article 25 of the Personal Information Protection Act, the Company specifies particulars in a contract in the event of the execution of an outsourcing agreement: prevention of personal information processing for other purposes than the initial purpose of the outsourcing; technical and managerial safeguards of personal information; restriction of re-outsourcing; management and supervision of the outsourcee; and matters on compensation and responsibilities.
  2. The Company also supervises how the outsourcee processes such personal information safely by inspecting the status of processing.

 

The Company shall be obligated to make public any modification or update to particulars of the outsourcee and outsourced work via the Policy without delay.

 

Article 6 Particulars of Personal Information to be Processed and Processing Methods thereof

  1. The Company processes the following particulars of personal information.
  1. Subscribers to website newsletters: E-mail address
  2. General information concerning medical professionals including doctors
    • Necessary information to collect: Name, postal address, date of birth, gender, phone number, e-mail address, organization, qualifications, department, specialty, academic background, work experience, publications, theses, etc.
    • Optional information to collect: License number, etc.
  1. Data concerning user complaints and reports on adverse events and other safety and quality issues
    • Necessary information to collect: Name, date of birth or age, phone number, postal address, e-mail address, etc.
    • Optional information to collect: Health information (area to be treated, field of inquiry, product information, particulars of safety-related information, duration, etc.), in-charge hospital and doctor (field of specialty, employment status and organization), etc.
  2. General data on job candidates
    • Necessary information to collect: Name, postal address, nationality, phone number, eligibility for compensation and benefits for veterans and persons with disabilities, academic background and performance, status of military service, work experience, intellectual property, theses, publications, research performance, overseas experience, professional experience, social activities, community service, language proficiency and other qualifications, cover letter, etc.
    • Optional information to collect: ID picture, date of birth, academic background, certificates, work experience, language proficiency, personal information described in a resume and other information that a job applicant consents to the collection thereof
  3. General data regarding subcontractors and suppliers
    • Necessary information to collect: Name, company name, business registration number, bank account number and postal address
    • Optional information to collect: Phone number, e-mail address, fax number, login ID, password, etc.
  1. The Company collects personal information prescribed by Subparagraph 1 by any of the following methods or processes:
  • Where clients create an account to use a product
  • Where feedback or a complaint on a product is submitted
  • Where job candidates apply for the Company and executives or employees work at the Company
  • Where an agreement with a subcontractor or supplier is executed

 

Article 7 Destruction of Personal Information

The Company shall destroy personal information without delay when the personal information becomes unnecessary owing to the expiry of the retention period, attainment of the purpose of processing the personal information, etc. The procedures, deadline and methods of destroying personal data are stated as follows.

  1. Procedures of destruction

Personal information is transmitted to an independent database (or separate document in the case of personal information written on paper) when the retention period expires or the purposes of retention are attained. Such personal information is destroyed without delay after being retained during a particular period prescribed by internal guidelines or relevant statutes. Once personal information is transmitted to the aforesaid database, the personal information shall not be used for any purpose other than the purpose for which the said personal information is used.

  1. Methods of destruction

Paper documents containing personal information shall be shredded or incinerated. Personal information in electronic files shall be permanently erased not to restore data.

 

Article 8 Measures to Ensure Safety of Personally Identifiable Information

The Company has technical, managerial and physical safeguards in place to ensure the safety of personal information in accordance with Article 29 of the Personal Information Protection Act as follows.

  1. Managerial measures

Establishment and implementation of internal management plans, regular employee training programs, etc.

  1. Technical measures

Access authority management for personal data processing systems, installation of access control software, encryption of personally identifiable information, installation of security programs, etc.

  1. Physical measures

Access control to computer rooms, archives, etc.

 

Article 9 Privacy Officers

  1. The Company has a privacy officer on duty as follows to ensure comprehensive responsibility for personal information processing; and handle data subjects’ grievances and remedial compensation relevant to personal information.

 

Privacy officer in charge

–    Name: Jae-hyung Park

–    Department and position: HR/CHO

–    Contact information: 02-515-6646 / apply@vuno.co

 

  1. Data subjects may make all types of inquiries arising out of using any of the Company’s services (or projects) on personal information and handling of grievances and remedial compensation to the privacy officer or the department in charge. The Company answers and handles inquiries from data subjects without delay.

 

Article 10 Matters on Installation, Operation and Rejection of Automatic Collection Equipment for Personal Information

The Company uses cookies to store and find user information. A cookie is a small text file containing information that a server used to run a website sends to a user browser, which is stored on a user’s computer hard drive. The Company uses cookies for the following purposes.

 

  1. Purpose of using cookies: To ensure improvements in the Company’s services by executing web analytics regarding user connection frequency and visiting times of members and non-members; and by keeping track of user preferences, fields of interest, digital footprints, access to online materials and visiting patterns.
  2. Type of cookies

Name

Function

Expiry time

Ccn

Prevention of CSRF (Cross-Site Request Forgery)

Session

Ci_session

Identification of users

Session

_ga

Transmission of data regarding user devices and website behaviors

One year

 

  1. Cookie rejection: Data subjects have the right to decide upon cookie installation. Cookie settings on a web browser enable data subjects to allow all cookies; be prompted with a window asking about consent for storing cookies; or block all cookies.
  2. Procedures of setting cookies (Internet Explorer)

– Tools in the browser toolbar > Internet Options > Privacy tab. Provided, if cookie installation is rejected, it may be difficult to use certain services.

 

Article 11 Installation and Operation of Visual Data Processing Equipment

The Company runs visual data processing equipment and manages the operation thereof.

  1. Purpose of installing visual data processing equipment: To provide on-premises security, prevent fire and crime and provide cooperation in case of crime investigation
  2. The number of equipment installed, locations and scope of recording thereof: One device for each entrance on each floor, where the Company’s headquarters offices are situated, keeps record of each lobby area and corridor (two for the fifth and sixth floors each; one for the eighth and tenth floors each).
  3. Person and department in charge and with access to visual data: Jin-young Lee, HR/GA Part
  4. Recording time, retention period, storage place and management method of visual data
  • Recording hours: 24 hours non-stop recording
  • Retention period: 90 days from the date of recording
  • Storage place and management method: HR/GA part in charge of management that is located on the eighth floor destroys stored personal data upon the expiration of retention period.
  1. Method and place of visual data confirmation: Contact the person in charge measures to deal with the request of data subjects for inspection of visual data: Request for inspection of visual data or request for checking the existence of data may be made to the operator of the visual data processing equipment. In such a case, an inspection of visual data may be allowed only if the person requesting it has been recorded as the subject of such recording, or if it is deemed obviously necessary in the physical safety and property interest thereof.
  2. Technical, administrative and physical measures to protect visual data:
  • Establishment and implementation of internal management plans, access control and restriction of access authority, introduction of storage and transmission technology to secure visual data, storage of processed data, forgery prevention, installation of storage space and security locks, etc.  
  1. Other matters concerning installation, operation and management of visual data processing equipment: The Company shall not operate any visual data processing device outside the scope reasonably related to the purposes for which visual data was initially collected according to relevant statutes; nor so as to look into the places which is likely to noticeably threaten individual privacy, such as a bathroom, restroom, sauna, and dressing room used by multiple unspecified persons. The Company shall not arbitrarily handle the visual data processing devices for other purposes than the initial one; nor use sound recording functions.

 

Article 12 Matters on Third Party Links

The Company’s website may include links to third party websites, plug-ins and application programs. A third party may collect or use a data subject’s personal information in the event of a click on a third party link or a connection thereto. The Company does not have any control of third party websites, plug-ins and application programs, and thus shall not be responsible or liable for any third party’s privacy policy.

 

Article 13 Modification of Privacy Policy

  1. The Policy takes effect on the date of execution. In the event that content is added, deleted or corrected in the Policy according to changes in relevant statutes and policies, the Company shall make public modified details via a notice section at least seven days before the new updated version of the privacy policy comes into effect.
  2. The Policy was modified and updated as follows.
  • Modified on January 1 2020; March 10 2020; and November 9 2020.